SCHEMBL18054178

SCHEMBL18054178

COc1cc(F)c2c(ccn2C(=O)OC(C)C)c1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGDR2 Q9Y5Y4 1/20 0.35
▸ LMNA P02545 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ BCHE P06276 1/20 0.33
▸ ECE1 P42892 1/20 0.33
▸ PDE4B Q07343 1/20 0.33
▸ PHGDH O43175 1/20 0.32
▸ ABHD6 Q9BV23 2/20 0.32
▸ HPGD P15428 1/20 0.31
▸ CACNA1H O95180 1/20 0.31
▸ P2RX4 Q99571 1/20 0.31
▸ TUBB4A P04350 1/20 0.30
▸ TUBB P07437 1/20 0.30
▸ TUBA3C P0DPH7 1/20 0.30
▸ TUBA1B P68363 1/20 0.30
▸ TUBA4A P68366 1/20 0.30
▸ TUBB4B P68371 1/20 0.30
▸ TUBB3 Q13509 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20977762 0.86 ACACB (0.36) LMNAHTTBCHE
SCHEMBL20224083 0.86 BCHE (0.32) BCHEECE1
SCHEMBL18054261 0.84 TNF (0.37) LMNAHTT
SCHEMBL18052987 0.83 MAPK1 (0.36) LMNAMAPK1HTTRAB9A
SCHEMBL20977771 0.83 BRPF1 (0.33) LMNARAB9AHPGD
SCHEMBL20227289 0.81 KDM4E (0.38) HTTPDE4B
SCHEMBL18054225 0.80 BCHE (0.34) PTGDR2LMNAMAPK1HTTRAB9A
SCHEMBL20977760 0.79 ALDH1A1 (0.36) LMNAMAPK1
SCHEMBL20224091 0.75 ACLY (0.35) —
SCHEMBL20977774 0.74 TFPI2 (0.40) PTGDR2LMNAMAPK1HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10766879-B2 Pyrimidine derivatives as kinase inhibitors and their therapeutical applications NANTBIOSCIENCE, INC. (US) 2020-09-08 — — US disclosed
US-20180155327-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS NANTBIOSCIENCE, INC. 2018-06-07 — — US disclosed
WO-2016137506-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS NANTBIOSCIENCE, INC. (US) 2016-09-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10766879-B2 Pyrimidine derivatives as kinase inhibitors and their therapeutical applications DCK, TK1, DTYMK PTGDR2 2486/4885LMNA 3575/4885MAPK1 402/4885
US-20180155327-A1 PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS DCK, TK1, DTYMK PTGDR2 2486/4885LMNA 3575/4885MAPK1 402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback